Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Navitas Semiconductor Corporation Common Stock (NVTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Navitas Semiconductor Corporation Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Navitas Semiconductor Corporation Common Stock trades at $9.08 (market cap $2.63B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 3.4× Navitas Semiconductor Corporation Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Navitas Semiconductor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Navitas Semiconductor Corporation Common Stock for 3 Days on average.
| KYMR | NVTS | |
|---|---|---|
Market Cap | $8.87B | $2.63B |
Volume | 779,107 | 20,633,069 |
Sector | Health | Technology |
52-Week High | $127.31 | $31.79 |
52-Week Low | $55.80 | $7.14 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $8.26B | $2.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Navitas Semiconductor (NVTS) trades at $10.45, up 4.6% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal overall, with moving averages indicating selling pressure, but oscillators suggest some bullish momentum. Fundamentally, the company is in a growth investment phase, reporting negative net income margins and significant cash burn from operations, offset by strong financing inflows. Recent news highlights strategic collaborations with NVIDIA and Microchip for AI data center power solutions and a U.S. Army contract for silicon carbide chip development, positioning NVTS in high-growth power semiconductor markets.
The outlook for NVTS hinges on execution in the AI and defense power semiconductor segments, with a consensus price target of $16.65 implying substantial upside. However, high valuation multiples, persistent losses, and competitive intensity pose significant risks. Investors should weigh the company's promising market positioning against its current lack of profitability and the capital-intensive nature of its expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Navitas Semiconductor Corporation Common Stock
Navitas Semiconductor designs and markets gallium nitride and silicon carbide power semiconductors. Its products are used in power conversion and charging for data centers, energy infrastructure, and industrial applications.
Read more on NVTS →
